Psoriatic arthritis is a potentially destructive, inflammatory joint disease that affects 20% to 30% of patients with psoriasis. Psoriasis precedes the onset of joint inflammation by approximately 10 years, providing a unique opportunity to intervene and prevent or delay onset of musculoskeletal manifestations. The emergence of sensitive imaging modalities and cellular biomarkers may facilitate early identification of patients with psoriasis who have subclinical joint disease and might help stratify patients with an early onset of arthritis.
Methods
The translational studies described herein are focused on the development of cellular biomarkers identified with flow cytometry and cell culture techniques in patients with psoriasis and psoriatic arthritis.
Results and Conclusion
The combination of power Doppler ultrasound imaging and cellular biomarkers (ie, CD16 and dendritic cell specific transmembrane protein) to diagnose early psoriatic arthritis and to stratify patients with established psoriatic arthritis provides a new opportunity to optimize treatment outcomes in this potentially disabling disease.
KaneD., StaffordL., BresnihanB., FitzGeraldO.A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology (Oxford).2003; 42: 1460–8.
5.
MeaseP.J.Psoriatic arthritis: Treatment update. Bull NYU Hosp Jt Dis.2011; 69: 243–9.
6.
KingsleyG.H., KowalczykA., TaylorH.A randomized placebo-controlled trial of MTX in PsA. Rheumatology (Oxford). doi: 10.1093/rheumatology/kes001 [E-pub ahead of print on February 17, 2012].
7.
GladmanD.D., ThavaneswaranA., ChandranV., CookR.J.Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?Ann Rheum Dis.2011; 70: 2152–4.
8.
GladmanD.D., ShuckettR., RussellM.L., ThorneJ.C., SchachterR.K.Psoriatic arthritis (PSA): An analysis of 220 patients. Q J Med.1987; 62: 127–41.
9.
AnandarajahA.P., RitchlinC.T.The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol.2009; 5: 634–41.
10.
O'RiellyD.D., RahmanP.Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev Rheumatol.2011; 7: 718–32.
11.
OgdieA., GelfandJ.M.Identification of risk factors for psoriatic arthritis: Scientific opportunity meets clinical need. Arch Dermatol.2010; 146: 785–8.
12.
HustedJ.A., ThavaneswaranA., ChandranV.Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care Res (Hoboken).2011; 63: 1729–35.
13.
JamnitskiA., SymmonsD., PetersM.J., SattarN., McIinnesI., NurmohamedM.T.Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review. Ann Rheum Dis. doi: 10.1136/annrheumdis-2011-201194 [E-pub ahead of print on April 24, 2012].
14.
BaetenD., DemetterP., CuvelierC.Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: Influence of disease duration and activity. Ann Rheum Dis.2000; 59: 945–53.
15.
KruithofE., BaetenD., De RyckeL.Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther.2005; 7: R569–80.
16.
NestleF.O., KaplanD.H., BarkerJ.Psoriasis. N Engl J Med.2009; 361: 496–509.
17.
GottliebA., MenterA., MendelsohnA.Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet.2009; 373(9664): 633–40.
18.
RitchlinC.Psoriatic disease: From skin to bone. Nat Clin Pract Rheumatol.2007; 3: 698–706.
19.
WagnerE.F., SchonthalerH.B., Guinea-ViniegraJ., TschachlerE.Psoriasis: What we have learned from mouse models. Nat Rev Rheumatol.2010; 6: 704–14.
20.
NameyT.C., RosenthallL.Periarticular uptake of 99mtechnetium diphosphonate in psoriatics: Correlation with cutaneous activity. Arthritis Rheum.1976; 19: 607–12.
21.
OffidaniA., CelliniA., ValeriG., GiovagnoniA.Subclinical joint involvement in psoriasis: Magnetic resonance imaging and X-ray findings. Acta Derm Venereol.1998; 78: 463–5.
22.
GisondiP., TinazziI., El-DalatiG.Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: A hospital-based case-control study. Ann Rheum Dis.2008; 67: 26–30.
23.
GutierrezM., FilippucciE., De AngelisR.Subclinical entheseal involvement in patients with psoriasis: An ultrasound study. Semin Arthritis Rheum.2011; 40: 407–12.
24.
NaredoE., MöllerI., de MiguelE.High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: A prospective case-control study. Rheumatology (Oxford), 2011; 50: 1838–48.
25.
GelfandJ.M., WanJ., Callis DuffinK.Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol.2012; 148: 487–94.
26.
HonigsmannH.Phototherapy for psoriasis. Clin Exp Dermatol.2001; 26: 343–50.
27.
MenterA., KormanN.J., ElmetsC.A.Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol.2010; 62: 114–35.
WeichenthalM., SchwarzT.Phototherapy: How does UV work?Photodermatol Photoimmunol Photomed.2005; 21: 260–6.
30.
VahlquistC., LarssonM., ErnerudhJ., BerlinG., SkoghT., VahlquistA.Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation. Arthritis Rheum.1996; 39: 1519–23.
31.
WilfertH., HönigsmannH., SteinerG., SmolenJ., WolffK.Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol.1990; 122: 225–32.
32.
MensahK.A., SchwarzE.M., RitchlinC.T.Altered bone remodeling in psoriatic arthritis. Curr Rheumatol Rep.2008; 10: 311–7.
33.
VigneryA.Macrophage fusion: The making of osteoclasts and giant cells [comment]. J Exp Med.2005; 202: 337–40.
34.
JonesD., GlimcherL.H., AliprantisA.O.Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest.2011; 121: 2534–42.
35.
RitchlinC.T., Haas-SmithS.A., LiP., HicksD.G., SchwarzE.M.Mechanisms of TNF-alpha– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest.2003; 111: 821–31.
36.
AnandarajahA.P., SchwarzE.M., TottermanS.The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis.2008; 67: 296–301.
37.
RitchlinC., ShaoT., DurhamR., LaudanskiK., Miller-GrazianoC., SchwarzE.M.Divergent pathways of monocyte effector cell differentiation in immune-mediated inflammatory disorders. Arthritis Rheum.2005; 52: S391.
38.
Ziegler-HeitbrockH.W.Heterogeneity of human blood monocytes: The CD14+ CD16+ subpopulation. Immunol Today.1996; 17: 424–8.
39.
Strauss-AyaliD., ConradS.M., MosserD.M.Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol.2007; 82: 244–52.
40.
Ziegler-HeitbrockL.The CD14+ CD16+ blood monocytes: Their role in infection and inflammation. J Leukoc Biol.2007; 81: 584–92.
41.
FingerleG., PforteA., PasslickB., BlumensteinM., StröbelM., Ziegler-HeitbrockH.W.The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood.1993; 82: 3170–6.
42.
ToddI., RadfordP.M., Ziegler-HeitbrockL., GhaemmaghamiA.M., PowellR.J., TigheP.J.Elevated CD16 expression by monocytes from patients with tumor necrosis factor receptor–associated periodic syndrome. Arthritis Rheum.2007; 56: 4182–8.
43.
TakeyamaN., YabukiT., KumagaiT., TakagiS., TakamotoS., NoguchiH.Selective expansion of the CD14(+)/CD16(bright) subpopulation of circulating monocytes in patients with hemophagocytic syndrome. Ann Hematol.2007; 86: 787–92.
44.
NockherW.A., ScherberichJ.E.Expanded CD14+ CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis. Infect Immun.1998; 66: 2782–90.
45.
ChiuY.G., ShaoT., FengC.CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther.2010; 12: R14.
46.
KukitaT., NaohisaW., KukitaA.RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med.2004; 200: 941–6.
47.
SawataniY., MiyamotoT., NagaiS.The role of DC-STAMP in maintenance of immune tolerance through regulation of dendritic cell function. Int Immunol.2008; 20: 1259–68.
48.
YagiM., MiyamotoT., SawataniY.DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med.2005; 202: 345–51.
49.
YagiM., MiyamotoT., ToyamaY., SudaT.Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J Bone Miner Metab.2006; 24: 355–8.
50.
IwasakiR., NinomiyaK., MiyamotoK.Cell fusion in osteoclasts plays a critical role in controlling bone mass and osteoblastic activity. Biochem Biophys Res Commun.2008; 377: 899–904.
51.
ChiuY.H., MensahK.A., SchwarzE.M.Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res. doi: 10.1002/jbmr.531 [E-pub ahead of print on October 10, 2011].
52.
WilkeC.M., BishopK., FoxD., ZouW.Deciphering the role of Th17 cells in human disease. Trends Immunol.2011; 32: 603–11.
53.
KryczekI., BruceA.T., GudjonssonJ.E.Induction of IL-17+ T cell trafficking and development by IFN-gamma: Mechanism and pathological relevance in psoriasis. J Immunol.2008; 181: 4733–41.
54.
WilsonN.J., BonifaceK., ChanJ.C.Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol.2007; 8: 950–7.
55.
LowesM.A., KikuchiT., Fuentes-DuculanJ.Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol.2008; 128: 1207–11.
56.
ZabaL.C., CardinaleI., GilleaudeauP.Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med.2007; 204: 3183–94.
57.
KruegerG.G., LangleyR.G., LeonardiC.A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med.2007; 356: 580–92.
58.
LeipeJ., GrunkeM., DechantC.Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum.2010; 62: 2876–85.
59.
ChiuY.G., SchwarzE.M., WojciechowskiW.Identification of a unique subset of DC-STAMP (dendritic cell-specific transmembrane protein) T cells with a Th17 signature in psoriatic arthritis (PsA) patients [abstract]. Arthritis Rheum.2011; 63(suppl 10): 1704.
60.
TobererF., SykoraJ., GöttelD.Tissue microarray analysis of RANKL in cutaneous lupus erythematosus and psoriasis. Exp Dermatol.2011; 20: 600–2.
61.
DominguezP., HusniM.E., GargA., QureshiA.A.Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire and the role of dermatologists: A report from the GRAPPA 2009 annual meeting. J Rheumatol.2011; 38: 548–50.
